[HTML][HTML] Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study
M Chai, H Zhang, L Yang, J Liang, H Han… - Chinese Medical …, 2023 - mednexus.org
Low-density lipoprotein cholesterol (LDL-C) is an independent risk factor for atherosclerotic
cardiovascular disease (ASCVD). Even after lipid-lowering therapy (LLT) with statins or …
cardiovascular disease (ASCVD). Even after lipid-lowering therapy (LLT) with statins or …
[PDF][PDF] Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study
M Chai, H Zhang, L Yang, J Liang, H Han… - Chinese Medical …, 2023 - scienceopen.com
Low-density lipoprotein cholesterol (LDL-C) is an independent risk factor for atherosclerotic
cardiovascular disease (ASCVD). Even after lipid-lowering therapy (LLT) with statins or …
cardiovascular disease (ASCVD). Even after lipid-lowering therapy (LLT) with statins or …
Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study
M Chai, H Zhang, L Yang, J Liang… - Chinese medical …, 2023 - pubmed.ncbi.nlm.nih.gov
Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular
risk: a single-center study Lipid lowering effects and safety of evolocumab in Chinese patients at …
risk: a single-center study Lipid lowering effects and safety of evolocumab in Chinese patients at …
Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study
C Meng, H Zhang, L Yang, J Liang… - Chinese Medical …, 2023 - search.proquest.com
Low-density lipoprotein cholesterol (LDL-C) is an independent risk factor for atherosclerotic
cardiovascular disease (ASCVD). Information regarding demographic characteristics …
cardiovascular disease (ASCVD). Information regarding demographic characteristics …
[HTML][HTML] Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study
M Chai, H Zhang, L Yang, J Liang, H Han… - Chinese Medical …, 2023 - journals.lww.com
Low-density lipoprotein cholesterol (LDL-C) is an independent risk factor for atherosclerotic
cardiovascular disease (ASCVD). Even after lipid-lowering therapy (LLT) with statins or …
cardiovascular disease (ASCVD). Even after lipid-lowering therapy (LLT) with statins or …
Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study.
M Chai, H Zhang, L Yang, J Liang, H Han… - Chinese Medical …, 2023 - europepmc.org
Low-density lipoprotein cholesterol (LDL-C) is an independent risk factor for atherosclerotic
cardiovascular disease (ASCVD). Even after lipid-lowering therapy (LLT) with statins or …
cardiovascular disease (ASCVD). Even after lipid-lowering therapy (LLT) with statins or …
[HTML][HTML] Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study
M Chai, H Zhang, L Yang, J Liang, H Han… - Chinese Medical …, 2023 - ncbi.nlm.nih.gov
Low-density lipoprotein cholesterol (LDL-C) is an independent risk factor for atherosclerotic
cardiovascular disease (ASCVD). Even after lipid-lowering therapy (LLT) with statins or …
cardiovascular disease (ASCVD). Even after lipid-lowering therapy (LLT) with statins or …
[引用][C] Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study.
M Chai, H Zhang, L Yang, J Liang, H Han… - Chinese Medical …, 2023 - europepmc.org